Shopping Cart
- Remove All
- Your shopping cart is currently empty
DRF-1042, an orally active camptothecin analog, exhibits anticancer and insecticidal activities by inhibiting DNA topoisomerase I. It has been studied for its efficacy against solid tumors, including prostate and colon cancers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
5 mg | $64 | In Stock | |
10 mg | $106 | In Stock | |
25 mg | $218 | In Stock | |
50 mg | $349 | In Stock | |
100 mg | $562 | In Stock | |
1 mL x 10 mM (in DMSO) | $71 | In Stock |
Description | DRF-1042, an orally active camptothecin analog, exhibits anticancer and insecticidal activities by inhibiting DNA topoisomerase I. It has been studied for its efficacy against solid tumors, including prostate and colon cancers. |
In vitro | DRF-1042 displays excellent endostatin stability and good in vitro anticancer activity. It confronts a range of human cancer cell lines including multi-drug resistant (MDR) phenotypes [2]. |
In vivo | DRF-1042 treatment showed adverse myelosuppressive effects in clone formation assays against mouse, canine and human bone marrow cells. This supports the possibility of extending the dosing schedule in experimental and clinical studies [2]. |
Molecular Weight | 408.4 |
Formula | C22H20N2O6 |
Cas No. | 200619-13-2 |
Smiles | CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3C(OCCO)n1c2=O |
Relative Density. | 1.53 g/cm3 (Predicted) |
Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 30 mg/mL (73.46 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.